Brokerages Set Alumis Inc. (NASDAQ:ALMS) PT at $39.60

Shares of Alumis Inc. (NASDAQ:ALMS) have earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $38.60.

ALMS has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a research report on Monday, December 29th. Loop Capital set a $37.00 price objective on Alumis in a report on Wednesday, January 21st. Wall Street Zen raised shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Oppenheimer increased their target price on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Stifel Nicolaus began coverage on shares of Alumis in a report on Wednesday, February 25th. They issued a “buy” rating and a $44.00 price target for the company.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: HC Wainwright raised EPS estimates across Q1–Q4 and lifted FY2026/FY2027 outlooks (e.g., FY2026 from ($2.99) to ($2.89); Q1–Q4 tweaks), while maintaining a “Buy” rating and a $25 price target — this reduces projected losses and provides an analyst-backed upside case. HC Wainwright research coverage (summary)
• Positive Sentiment: Chardan Capital assigned a Buy rating, adding an additional institutional endorsement that can attract buyer interest. Alumis Earns Buy Rating from Chardan Capital
• Positive Sentiment: An Oppenheimer analyst is reported to expect the stock to rise, reinforcing bullish sentiment from multiple brokers and likely supporting demand. Oppenheimer bullish note
• Neutral Sentiment: General market coverage (CNN) lists ALMS among tracked stocks; broad news distribution can increase visibility but doesn’t by itself change fundamentals. CNN: Alumis Inc.
• Neutral Sentiment: A news piece with a contrary headline referencing a “pessimistic forecast” appeared, but the underlying broker actions (above) show upward revisions and Buy ratings — treat the conflicting headlines cautiously. HC Wainwright pessimistic forecast article

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $22.73 on Thursday. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -7.43 and a beta of -0.61. The stock has a 50 day moving average price of $26.34 and a 200 day moving average price of $14.85. Alumis has a 52-week low of $2.76 and a 52-week high of $30.60.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The firm had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%. Analysts forecast that Alumis will post -8.51 earnings per share for the current year.

Insider Buying and Selling at Alumis

In other Alumis news, major shareholder Foresite Capital Management Vi acquired 411,764 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The shares were bought at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the completion of the acquisition, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. This represents a 7.78% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director James B. Tananbaum acquired 411,764 shares of Alumis stock in a transaction that occurred on Thursday, January 8th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the director directly owned 5,702,536 shares of the company’s stock, valued at $96,943,112. This represents a 7.78% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders purchased 1,823,527 shares of company stock valued at $30,999,959. 40.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. MPM Bioimpact LLC purchased a new stake in Alumis during the fourth quarter valued at approximately $23,443,000. Orbimed Advisors LLC purchased a new position in Alumis in the second quarter worth $5,779,000. Velan Capital Investment Management LP purchased a new position in Alumis in the second quarter worth $4,863,000. Woodline Partners LP increased its position in shares of Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after purchasing an additional 1,558,660 shares in the last quarter. Finally, Samsara Biocapital LLC increased its position in shares of Alumis by 47.0% during the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock worth $14,404,000 after purchasing an additional 1,534,872 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.